It is made available under a CC-BY 4.0 International license .

### Effects of Maternal Fortified Balanced Energy-Protein Supplementation on the Mother-Infant Gut Microbiome: A Sub-Study of the MISAME-III Randomized Controlled Trial

Lishi Deng<sup>1,\*</sup>, Steff Taelman<sup>2,3,4,\*</sup>, Matthew R. Olm<sup>5</sup>, Laéticia Céline Toé<sup>1,6</sup>, Eva Balini<sup>4</sup>, Lionel Ouédraogo<sup>1,7</sup>, Yuri Bastos-Moreira<sup>1,8</sup>, Alemayehu Argaw<sup>1</sup>, Kokeb Tesfamariam<sup>1</sup>, Erica D. Sonnenburg<sup>5</sup>, Moctar Ouédraogo<sup>9</sup>, Rasmané Ganaba<sup>9</sup>, Wim van Criekinge<sup>2</sup>, Patrick Kolsteren<sup>1</sup>, Michiel Stock<sup>2,3</sup>, Carl Lachat<sup>1</sup>, Justin L. Sonnenburg<sup>5,10,11</sup>, Trenton Dailey-Chwalibóg<sup>1,9</sup>

- 1 Department of Food Technology, Safety and Health, Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium.
- 2 BIOBIX, Department of Data Analysis and Mathematical Modelling, Ghent University, 9000 Ghent, Belgium
- 3 KERMIT, Department of Data Analysis and Mathematical Modelling, Ghent University, 9000 Ghent, Belgium
- 4 BioLizard nv, Ghent, Belgium
- 5 Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.
- 6 Institut de Recherche en Sciences de la Santé (IRSS), Unité Nutrition et Maladies Métaboliques.
- 7 Centre Muraz, Bobo-Dioulasso, Burkina Faso.
- 8 Center of Excellence in Mycotoxicology and Public Health, MYTOXSOUTH® Coordination Unit, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, Belgium
- 9 Agence de Formation de Recherche et d'Expertise en Santé pour l'Afrique (AFRICSanté), Bobo-Dioulasso, Burkina Faso.
- 10 Chan Zuckerberg Biohub, San Francisco, CA, USA.

11 Center for Human Microbiome Studies, Stanford University School of Medicine, Stanford, CA, USA.

\* These authors contributed equally to the work

Correspondence author: Trenton Dailey-Chwalibóg [Trenton@Dailey-Chwalibog.com]

#### Abstract

Biological pathways, including individual gut microbiome are potential barriers for maternal nutritional supplementation to improvement in infant growth. We evaluated the impact of balanced energy-protein (BEP) supplementation during pregnancy and the first six months of lactation on the composition and functionality of gut microbiome in mothers and their infants in rural Burkina Faso. Our findings reveal that BEP supplementation led to a significant increase in microbiome diversity during pregnancy. In the second trimester, there was a notable decrease in the abundance of an *Oscillospiraceae* species, while postpartum, the abundance of *Bacteroides fragilis* increased. We identified concerted enriched or depleted microbial pathways associated with BEP supplementation, including the phosphotransferase system, a critical mechanism for bacterial carbohydrates uptake, which exhibited enrichment in infants born to BEP-supplemented mothers. Despite these observations, the intricate biological connections with other omics necessitate further analysis to fully elucidate the underlying comprehensive biological pathways.

It is made available under a CC-BY 4.0 International license .

#### 1 Introduction

2 It estimated that 148.1 million children under the age of 5 – about 22% of the global population - experienced stunted growth in 2022, hindering their full developmental 3 potential<sup>1</sup>. Stunted growth commonly begins before birth, so-called fetal growth restriction 4 5 and accumulates during infancy until the age of 18 to 23 months; after 2 years of age, the growth impairment tends to be largely irreversible  $^{2-5}$ . Maternal undernutrition in pregnancy is 6 a major risk factor for poor child growth<sup>2,5</sup>. A growing body of research has investigated the 7 8 effect of maternal nutritional supplementation on infant growth, such as lipid-based nutrient supplement (LNS) and balanced energy-protein (BEP), but the results have been mixed<sup>6-10</sup>. 9 10 These findings suggest that the role of biological pathways needs to be considered.

11 From the first colonization of the neonate at birth through maternal microbiota, succession in bacterial taxa differ based on geographical area<sup>11-13</sup>, feeding practice<sup>14,15</sup>, dietary patterns, age, 12 and health status<sup>16,17</sup>. A more mature gut microbiota at the first month may improve infant 13 growth trajectories in the first year of life<sup>18</sup>. Inadequate maturation of the gut microbiome 14 15 might contribute to the onset of child malnutrition, and both microbiome immaturity and malnutrition can be partially ameliorated following nutrition interventions<sup>19,20</sup>. Therefore, 16 given its plastic nature, the individual gut microbiome appears to be a promising barrier to 17 18 improvement in growth outcomes.

The evidence on the effect of maternal nutritional supplementation on infant gut microbiome is scarce. Two analyses based on randomized controlled trials (RCTs) in Malawi showed inconsistent results. The first study (n = 869) revealed a significant enhancement in alpha diversity among infants receiving LNS from 6 to 18 months<sup>21</sup>, while the second study (n =631) demonstrated no statistically significant effects of LNS on the diversity and maturation of the infant gut microbiota in samples collected between 6 and 30 months of age<sup>22</sup>.

25 BEP supplements are a similar type of ready-to-use supplements that provide multiple 26 micronutrients and, specifically, energy and protein in a balanced composition (<25% of total 27 energy content from protein) to address maternal malnutrition during pregnancy and lactation. 28 We previously reported that, in the MIcronutriments pour la SAnté de la Mere et de l'Enfant-29 III (MISAME-III) trial, BEP supplementation increase energy and macro- and micronutrient intakes among pregnant women and fills nutrient gaps without displacing food intake<sup>23</sup>. 30 31 Moreover, we observed a modest effect of prenatal BEP supplementation on weight and 32 length increments at birth, and on the prevalence of low birth weight<sup>24</sup>. The improvements in

It is made available under a CC-BY 4.0 International license .

size at birth accrued from prenatal BEP supplementation were sustained in terms of linear
 growth at the age of 6 months<sup>7</sup>. However, the impact of providing pregnant and lactating
 women with BEP supplementation on gut microbiota has yet to be investigated.

The objective of the present study was to evaluate the efficacy of BEP supplementation during pregnancy and the first six months of lactation in influencing the gut microbiota in both mothers and infants, compared to the control group who received iron folic acid (IFA) tablets. This encompasses an examination of the maternal and infant metagenome in terms of microbial composition and functionality, including microbial metabolic pathways, a dimension that has not been explored in prior studies.

#### 42 **Results**

#### 43 Study population

44 A total of 731 fecal samples from 152 pregnant and lactating women and their infants (n = 7145 in BEP group and n = 81 in IFA group) were collected and sequenced; these comprised 256 46 infant samples and 475 maternal samples. In the IFA group, infant samples were taken at two 47 time points, 1-2 months (76 samples) and 5-6 months (56 samples) of life, and maternal 48 samples were taken at four time points, inclusion (i.e., trimester 2, 20 samples), trimester 3 49 (78 samples), 1-2 months (76 samples) and 5-6 months (75 samples) postpartum (total IFA 50 samples = 381). In the BEP group, 66 and 58 infant samples were taken at 1-2 months and 5-51 6 months of life, and 22, 71, 66 and 67 maternal samples were taken at inclusion, trimester 3, 52 1-2 months and 5-6 months postpartum (total BEP samples = 350) (Figure 1).

53 Baseline characteristics of study participants are presented in Table 1. The Mean age of the 54 study women was 24.27 (SD: 5.55) years, and the average body-mass index (BMI) was 22.37 kg/m<sup>2</sup>. The Mean gestational age at birth was 39.82 (SD: 1.72) weeks and more than one in 55 56 three had at least three prior pregnancies. More than half of the women were from food-57 insecure households, and 30.3% were anemic. Almost all infants were exclusively breastfed, 58 with an average duration of 5.78 months. Among all participants, the average compliance rate 59 of consuming the BEP supplement was 83.1% during the prenatal and 86.0% during the 60 postnatal supplementation periods.

#### 61 Deep sequencing of gut microbiome and the early colonization

62 Mean total sequencing depth of infant and maternal metagenomes was 8.03 (SD: 1.87) and

63 25.29 (SD: 5.28) giga base-pairs, respectively (Figure S1). 7.4% (SD: 1.7%) and 19.9% (SD:

It is made available under a CC-BY 4.0 International license .

64 18.8%) of metagenomic reads were removed from maternal and infant samples during QC 65 and human read decontamination. 58.1% (SD: 14.2%) of infant and 58.0% (SD: 3.0%) 66 maternal reads could be robustly assigned to genomes in our microbial genome database. Out 67 of the 2,654 unique genomes detected in at least one sample, 2,493 are unique to the maternal 68 population, 396 are unique to the infant population, and 235 are observed in both groups. 69 Among the shared microbial genomes, 205 are already observed in the mothers at prenatal 70 time points. The maternal gut microbiomes were dominated by Prevotella species, 71 representing a median of 37.9% of the composition, with no major shift between pre- and 72 postnatal compositions (38.1% and 37.7%). In the infant gut microbiomes, Prevotella 73 comprised between 0.0% and 83.9% of the gut microbiome, despite being only observed in 74 44 out of the 256 infant samples. In most infant samples, Bifidobacterium strains were 75 dominant, comprising a median of 44.5% of the microbial compositions and present in 98.0% 76 of infant samples (Figure 2A).

# BEP supplementation has minimal effect on prenatal gut microbiome composition anddiversity

79 The richness of the infant microbiota is markedly smaller than those of the mothers, with an 80 observed species index between 2 and 43 in the former and between 75 and 614 in the latter. 81 The Shannon diversity index has a median of 1.48 bits in the infant samples and 4.47 bits in 82 the maternal samples and is on average higher in the prenatal samples than in the postnatal 83 ones (Figure 2E). Using Targeted Maximum Likelihood Estimator (TMLE), a significant (p =84 0.037) effect of BEP is observed on the prenatal maternal microbiome diversity. The average 85 treatment effect is estimated at an increase in Shannon diversity index of 0.144 bits caused by 86 BEP supplementation (95% CI: 0.009 - 0.280). In effective numbers, this translates to an 87 estimated increase of 1.16 equally common species due to the treatment. No significant 88 average treatment effect was found on the postnatal (p = 0.97) and infant (p = 0.11) gut 89 microbiome diversities.

As illustrated in Figure 2B and 2C, beta-diversity analyses show diversification of the communities, with significant differences between samples taken at different stages of pregnancy (p = 0.002) or infancy (p = 0.001). In the maternal samples, a marginally significant (p = 0.098) inter-community difference is attributed to the BEP supplementation, though this effect is no longer observed in the infant samples (p = 0.960).

It is made available under a CC-BY 4.0 International license .

Differential abundance analyses in the maternal stool samples show significant associations between an *Oscillospiraceae* species [CAG-103 sp 000432375; *q*-value =  $2.48 \times 10^{-4}$ ; log fold change (logFC) = -1.12] and *Bacteroides fragilis* (*q*-value =  $3.26 \times 10^{-8}$ ; logFC = 1.31) and BEP supplementation, at inclusion and 5-6 months postpartum, respectively. No robustly significant associations were found between BEP supplementation and the microbial abundances in the infant stool at either time point (Figure 3 and Table S2).

#### 101 BEP supplementation shows coordinated enrichment of specific microbial pathways

102 Though no significant association was observed between the treatment intervention and the 103 abundance of individual microbial genes, the Gene Set Enrichment Analysis did indicate 104 concerted enrichment and depletion of certain microbial pathways at each time point (Figure 105 4). The gene set for the phosphotransferase system is found to be slightly depleted in the stool of BEP-supplemented mothers, both pre- and postpartum ( $p=2.56\times10^{-5}$  at tri3;  $p=2.23\times10^{-3}$  at 106 pn56) and enriched in stool of BEP-supplemented infants ( $p=2.67\times10^{-2}$  at pn12;  $p=2.76\times10^{-3}$ 107 at pn56). Pathways for lipopolysaccharide (LPS) biosynthesis ( $p=1.53\times10^{-4}$  at tri3; 108  $p=1.88\times10^{-2}$  at pn56), ABC transporters ( $p=2.27\times10^{-8}$  at tri3;  $p=1.17\times10^{-3}$  at pn56), 109 biosynthesis of cofactors ( $p=2.27\times10^{-8}$  at tri3;  $p=1.42\times10^{-2}$  at pn56), and porphyrin 110 metabolism ( $p=2.85\times10^{-3}$  at tri3;  $p=1.74\times10^{-2}$  at pn56) are slightly, but significantly depleted 111 in the BEP supplemented mothers at multiple time points. The pathway for the ribosome 112 113 complex is significantly enriched in the BEP-supplemented mothers at multiple time points  $(p=1.55\times10^{-6} \text{ at tri3}; p=1.17\times10^{-3} \text{ at pn56})$ . Other pathways, like those for flagellar assembly, 114 are enriched at inclusion  $(9.35 \times 10^{-5})$  yet depleted in the third trimester  $(p=1.45 \times 10^{-5})$  and 1-2 115 months postpartum ( $p=2.95\times10^{-8}$ ) in the BEP supplemented mothers. The full table of 116 117 significantly differential pathways is available in Table S3.

118 In Figure 5, we show that the gene set depletion of the LPS biosynthesis pathway affects 119 specific sections of sequential genes in the pathway. Every gene involved in the conversion 120 from UDP-N-acetyl-D-glucosamine to Lauroyl-KDO2-lipid IV(A) is less abundant with 121 logFC from -0.033 (LpxH) to -0.140 (LpxC). Only one enriched gene, HddA, appears in the 122 LPS biosynthesis pathway in another section of differentially abundant genes following the 123 pentose phosphate pathway. Analogous pathway visualizations are available for the 124 phosphotransferase system, flagellar assembly, and ABC transporters in Supplementary Data 125 (Figure S2-S4).

It is made available under a CC-BY 4.0 International license .

#### 126 **Discussion**

127 Here, we represent a rare combination of deep sequencing depth and high sample size on a population that is underrepresented in metagenomic literature<sup>25</sup>. We present three novel 128 129 findings. First, there is a striking disparity in composition of gut microbiome between 130 mothers and their infants in rural Burkina Faso - the infant gut microbiota exhibited a 131 conspicuous dominance of Bifidobacterium strains, while Prevotella species were dominant 132 in maternal samples. Second, BEP supplementation has minimal effect on maternal gut 133 microbiome - increased Shannon diversity and decreased the abundance of an 134 Oscillospiraceae species during pregnancy and increased the abundance of Bacteroides 135 fragilis postpartum. Finally, we observed multiple concerted enriched or depleted microbial 136 pathways associated with BEP supplementation, of which, the pathway phosphotransferase system, a major mechanism used by bacteria for uptake of carbohydrates<sup>26</sup>, is enriched in 137 138 infant samples whose mother were BEP-supplemented.

139 Bifidobacterium, commonly found in exclusively breastfed infants, are crucial in the infant 140 gut because they breakdown human milk oligosaccharides (HMO) to short chain fatty acids to maintain gut health<sup>27,28</sup>. In this study, nearly all infants, regardless of intervention groups, 141 142 experienced exclusive breastfeeding during the sample collection period. This circumstance 143 might explain the comparability in abundance patterns between the groups and suggests that 144 the provision of BEP during pregnancy and lactation exerted no discernible impact on the 145 primary beneficial colonizers or of their HMO utilization genes in infants. Previous 146 researches highlighting the prevalence of *Prevotella*-rich gut in non-industrialized 147 populations, particularly those adhering to high-fiber diets, in stark contrast to the lower occurrence observed in industrialized and westernized nations<sup>11,17,29</sup>. This distinct enterotype 148 149 characterized by Prevotella enrichment had also been noted in early childhood, spanning a wide age from 7 to 37 months, as observed in a Gambian cohort<sup>29</sup>. Interestingly, we observed 150 151 a strong tie of *Prevotella* between microbial genomes in mother and infant samples. In the 152 latter, Prevotella was either markedly absent or notably abundant, implying its swift 153 dominance within the ecological niche upon establishing residence within the infantile gut.

Gut microbiome alpha diversity has been linked to human health, with lower levels of diversity associated with several acute and chronic disease<sup>30</sup>. Recent studies have reported a noteworthy association between a high-fat diet and a decrease alpha diversity, concomitant with the onset of low-grade inflammation<sup>31,32</sup>. This in turn facilitate the increase and

It is made available under a CC-BY 4.0 International license .

translocation of bacterial products such as pro-inflammatory LPS<sup>33</sup>. Intriguingly, our findings 158 159 indicate the contrary: an augmentation in alpha diversity and a concurrent decrease in LPS 160 synthesis within the prenatal gut microbiota in women who received BEP. The subsection of 161 the LPS biosynthesis pathway which is depleted, *i.e.*, the central KDO and Lipid A 162 metabolism, is highly conserved and invariant in the gut microbiome of healthy individuals<sup>34</sup>. 163 Given that different covalent modifications of Lipid A also have different immunological properties<sup>35,36</sup>, follow-up research integrating proteomics and metabolomics data is currently 164 165 ongoing to fully understand the clinical implications of these findings.

166 The observed significant variation in alpha diversity within the maternal gut microbiota 167 during pregnancy, without a corresponding effect among infants, suggests that the maternal 168 component of BEP supplementation did not exert a detectable influence on the diversity of 169 child's microbiome. This aligns with the observations stemming from an LNS intervention 170 conducted in rural Malawi<sup>21</sup>.

171 We observed a significant association between BEP supplementation during the second 172 trimester and a reduction in the abundance of CAG-103 sp000432375, an Oscillospiraceae species that has recently been recognized as responsive to carbohydrates<sup>37</sup>. The overall lesser 173 174 dependence on carbohydrate metabolism can also be observed in the concerted depletion of 175 genes for the phosphotransferase system and ABC transporters in the maternal 176 metagenomes<sup>38,39</sup>. In addition, BEP supplementation is associated with increased abundance 177 of Bacteroides fragilis within the maternal gut at 5-6 months postpartum. B. fragilis is a 178 major component of the fecal microbiome, with potentially billions of *B. fragilis* within the gastrointestinal tract<sup>40</sup>, and plays a crucial role in the degradation of host-derived mucosal 179 180 glycans, including mucins and the *N*-link oligosaccharides of glycoproteins<sup>41</sup>. Nevertheless, 181 during the third trimester, a contrasting association was observed between BEP 182 supplementation and another strain of *B. fragilis*. However, it is important to exercise caution 183 when interpreting this finding, as it did not withstand the sensitivity analysis for pseudo-184 counts, suggesting the possibility of a false positive result.

Despite the potential for false positives, BEP supplementation appears to exhibit an association with the increases in the abundance of *Campylobacter jejuni*, and *Veillonella parvula* and *Klebsiella quasipneumoniae* during the first two months and at the five-to-six months of early life, respectively. In LMICs, infection with *Campylobacter* is one of the major causes of diarrheal disease in children<sup>42</sup>, leading to early protein malnutrition<sup>43</sup>. A

It is made available under a CC-BY 4.0 International license .

190 recent study has reported higher rates of campylobacteriosis among exclusively breastfed 191 infants in LMICs. It suggests that specific C. jejuni strains can utilize HMO and proteins in human milk to promote the growth of campylobacters<sup>44</sup>. Similarly, another study revealed 192 193 that the content of the secretory immunoglobulin A (sIgA) in breastmilk was positively 194 correlated with the abundance of V. parvula in infant gut microbiota, and suggested that this 195 regulation during early life is one of the potential mechanisms by which sIgA in breast milk modulates immune function<sup>45</sup>. Klebsiella pneumoniae, comprising K. quasipneumoniae, is a 196 leading pathogen for neonatal infection<sup>46,47</sup>. A recent study has reported the association of the 197 198 high abundance of Klebsiella and high content of breast milk N-acetylneuraminic acid 199 (Neu5Ac), the predominant form of free salic acid and important component binding to 200 sialylated oligosaccharides in breast milk, which indicates that *Klebsiella* could utilize sialic acid as carbon source<sup>48</sup>. Hence, the observed connection between BEP supplementation and 201 202 increased abundance of these species in the infant gut microbiome imply that BEP 203 supplementation during pregnancy and lactation may influence the infant microbiome by 204 impacting the composition of human milk. However, further analyses aimed at evaluating the 205 effect of BEP supplementation on breastmilk composition are imperative to gain a more 206 comprehensive understanding of these observations.

207 We identified that the phosphotransferase system, a critical mechanism for bacterial 208 carbohydrates uptake, exhibited enrichment in infants born to BEP-supplemented mothers. 209 This implies that the provision of BEP supplementation to mothers may elevate carbohydrate 210 content in human milk, thereby augmenting the bacterial carbohydrates uptake capacity 211 within the infant gut, potentially contributing to enhanced linear growth. However, 212 subsequent analyses, incorporating a detailed evaluation of human milk components and 213 employing a multi-omics approach are imperative for a comprehensive understanding of the 214 intricate biological pathways.

Some significantly differential pathways were found that are unlikely to be of microbial origin, such as those for the ribosome complex, the biosynthesis of cofactors, and porphyrin metabolism. Though the observation of these pathways is likely a limitation of the KEGG database these genes were annotated with, their consistent association to the BEP supplemented metagenome can be indication that there are so far unknown microbial processes that involve these genes.

221

It is made available under a CC-BY 4.0 International license .

#### 222 Methods

#### 223 Study setting and design

The MISAME-III study protocol<sup>49</sup> and the biospecimen sub-study (Biospé)<sup>50</sup> were published earlier. Briefly, the MISAME-III trial (NCT03533712) is an individually randomized 2 x 2 factorial RCT evaluating the efficacy of multiple micronutrient-fortified BEP supplementation during pregnancy and lactation on birth outcomes and infant growth in rural Burkina Faso. Biospé study, which was nested within the MISAME-III trial, aimed to evaluate the physiological effects of BEP supplementation on both pregnant and lactating women and their infants.

The study was implemented in six rural health center catchment areas in the district of Houndé in the Hauts-Bassins region of Burkina Faso from October 2019 to December 2020. A total of 1,897 women aged between 15 and 40 years with a gestational aged < 21completed weeks, and living in the study catchment villages, were enrolled in this trial. The habitual diet during pregnancy is nondiverse<sup>51</sup>, being predominantly based on maize with a supplement of leafy vegetables<sup>52</sup>.

237 Women were randomly assigned to the prenatal intervention arms receiving either fortified 238 BEP supplements and iron-folic acid (IFA) tablets (i.e., intervention) or IFA alone (i.e., 239 control), which is the standard of care during pregnancy in Burkina Faso. The same women 240 were concurrently randomized to receive either of the postnatal interventions, which 241 comprised fortified BEP supplementation during the first six months postpartum in 242 combination with IFA for the first 6 weeks (i.e., intervention), or the postnatal control, which 243 comprised IFA alone for six weeks postpartum (i.e., control). Therefore, there were four study 244 groups in MISAME-III study: (1) prenatal BEP and IFA supplementation; (2) postnatal BEP 245 and IFA supplementation; (3) both pre- and postnatal BEP and IFA supplementation; or (4) 246 both pre- and postnatal IFA only supplementation.

#### 247 Study supplements

The BEP supplement is a lipid-based nutrient supplement in the form of an energy-dense peanut paste fortified with multiple micronutrients. The BEP is produced by Nutriset and is ready-to-consume, does not require a cold chain and is highly stable with a long shelf life. The complete nutritional composition of a daily dose of the fortified BEP is provided in S1 Table. On average, a daily dose of the BEP (72g) provided an energy top up of 393 kcal (36%

It is made available under a CC-BY 4.0 International license .

energy from lipids, 20% from protein, and 32% from carbohydrates) and covered at least the estimated average nutritional requirements of pregnant women for 11 micronutrients, except calcium, phosphorous, and magnesium<sup>53</sup>. A daily dose of an IFA tablets (Sidhaant Life Science, Delhi, India) contained 65 mg of iron [form: FeH<sub>2</sub>O<sub>5</sub>S] and 400  $\mu$ g folic acid [form: C<sub>19</sub>H<sub>19</sub>N<sub>7</sub>O<sub>6</sub>]. Following Burkinabè guidelines, all enrolled women received malaria prophylaxis (three oral doses of sulfadoxine-pyrimethamine).

#### 259 Fecal sample collection

260 As a sub-analysis of Biospé study, fecal samples from mother-infant dyads were collected in 261 all four groups but only two groups of samples, both pre- and postnatal BEP and IFA 262 supplementation group (BEP group), and both pre- and postnatal IFA only supplementation 263 group (IFA group) have been sequenced. Maternal fecal samples (8g) were collected in a 264 fecal pot and then aliquoted into sterile cryotubes (Biosigma, Cona, VE, Italy), flash-frozen 265 and transferred to a -80  $\circ$ C freezer. Infant feces (8g) were collected using a 38  $\times$  50 cm sterile 266 protection sheet (Kimberley-Clark, Irving, TX, USA) which is used like a diaper and 267 wrapped around the newborn, before they were transferred to a OMNIgene•GUT OM-200 268 collection kit and then sterile cryotubes for storage at -80 °C. The collected feces were 269 assessed for consistency based on the visual Bristol scale. For liquid feces, thorough 270 homogenization was performed using a plastic spoon to mix the solid and liquid.

Fecal samples were collected from the pregnant and lactating women at inclusion into the Biospé study when most of the women were in trimester 2 (19-24 weeks) and have been taken supplementation for 2-3 weeks, trimester 3 (30-34 weeks) and 1-2 (28-56 days) and 5-6 months (147-175 days) postpartum. Infant fecal samples were collected in 1-2 months (12-56 days of life) and 5-6 months (140-168 days of life) corresponding to maternal postnatal time points.

#### 277 Metagenomic library preparation and sequencing

DNA extraction, library preparation, and metagenomic sequencing was performed at the UC
San Diego IGM Genomics Center. DNA extraction was performed using the Thermo
MagMAX Microbiome Ultra kit. DNA quantification was performed using picogreen dye.
Roche KAPA HyperPlus and 96-UDI plates were used for library preparation. In this study,
25ng of input DNA and 9 PCR cycles were used during library preparation. A shallow MiSeq
Nano sequencing run was used to normalize read sequencing depth. 2 x 150bp reads were

It is made available under a CC-BY 4.0 International license .

then generated on the Illumina NovaSeq 6000 at a target depth of 25 giga base-pairs per sample for maternal samples and 10 giga base-pairs per sample for infant samples.

#### 286 Metagenomic read annotation

287 The metagenomic sequencing reads were trimmed and deduplicated using FastP. All reads 288 mapping to the hg38 human genome with Bowtie2 under default settings were removed. 289 Samples were profiled by mapping preprocessed reads from each sample to a previously 290 established database of microbiome genomes (database "Deltal") using Bowtie2 with default 291 settings. The DeltaI microbial genome database was specifically created to profile nonindustrialized infant microbiomes<sup>13</sup>. The resulting mapping files were analyzed using inStrain 292 profile under default settings<sup>54</sup>. Relative abundance of each genome was calculated using the 293 294 formula: number of reads mapping to genome / number of processed reads in sample. Only 295 genomes with breadth > 0.5 were considered in analyses.

296 Gene-level functional profiling was performed using the inStrain "parse\_annotations" 297 pipeline with default settings 298 (https://instrain.readthedocs.io/en/master/user manual.html#parse-annotations). Genes were 299 called for each genome individually using Prodigal in "single" mode, and all gene files were 300 then concatenated together. Functional annotation was performed against (1) Kyoto 301 Encyclopedia of Genes and Genomes (KEGG) Orthologies (KOs) using kofam scan (version 302 1.3); (2) carbohydrate-active enzymes (CAZymes) using dbCAN2 (version 11); (3) 303 Comprehensive Antibiotic Resistance Database (CARD) Anti-Microbial Resistance (AMR) 304 database version 3.2.5 using Diamond with the command "diamond blastp -f 6 -e 0.0001 -k 305 1"; and (4) HMO proteins using the instructions provided here: 306 https://instrain.readthedocs.io/en/master/user manual.html#human-milk-oligosaccharide-

307 <u>hmo-utilization-genes</u>.

#### 308 Taxonomic data analysis

Alpha-diversity metrics for Observed Species index, Simpson's Diversity index, and Shannon Diversity index were calculated in R using phyloseq v1.44.0<sup>55</sup>. The treatment effect of the randomized intervention was estimated by the doubly robust TMLE in R using tmle v1.5.0<sup>56</sup>. Given the likely heterogeneity of the effect between the populations, this estimation was performed for maternal and infant data separately, further separated into pre- and postnatal for the maternal samples. Maternal stratum data (level of education, marital status, language, religion, ethnicity, number of jobs, socio-economic status, dietary diversity score, and health

It is made available under a CC-BY 4.0 International license .

center), as well as anthropometric data taken at inclusion into the trial (age, height, BMI and
hemoglobin level) were taken as covariates for the model. Both covariate-outcome and

propensity score models were fitted with ensemble SuperLearner (v2.0-28) models. Diversity

indices were translated to effective numbers of species using the formulas posed by  $Jost^{57}$ .

- Beta-diversity analysis was performed in R using vegan v2.6-4. Ordination was performed on the weighted UniFrac distances between the log transformed strain counts, followed by multivariate statistics between groups using permutational multivariate analysis of variance
- 323 (PERMANOVA) with default parameters.

To address compositionality and zero-inflation issues of microbial count data, the differential abundance analyses was performed by using Analysis of Compositions of Microbiomes with Bias Correction (ANCOM-BC) v2.2.1 at every taxonomic level separately to identify taxa associated to the treatment intervention<sup>58</sup>. Benjamini-Hochberg multiple testing correction was used, and the alpha-level was set at 0.05. To avoid inflated false positive rate, a sensitivity analysis was conducted against the addition of pseudo-counts. Only robustly significant taxa were reported.

#### 331 Functional data analysis

A hierarchical differential abundance analyses was conducted on the Trimmed Mean of Mvalues (TMM) library sizes for the gene counts using treeclimbR v0.1.5 and edgeR in R<sup>59</sup>. Genes from KEGG, HMO, CAZyme and CARD were categorized into a hierarchical structure based on their respective Enzymatic Class (EC) number, functional group, HMO cluster or antibiotic resistance mechanism. Benjamini-Hochberg multiple testing correction was used, and the alpha-level was set at 0.05.

Using the KEGG pathway mappings, we performed a Gene Set Enrichment Analysis to identify pathways that were differentially abundant in a coordinated direction<sup>60</sup>. A *Bifidobacterium longum* NagR regulon gene set was also added for the HMO utilization genes found in Table 1 of Arzamasov et. al (2022)<sup>61</sup>. For each set, an enrichment score with a corresponding adjusted p-value was calculated in R using clusterProfiler v4.2.2<sup>62</sup>. The alphalevel was set at 0.05 and the minimum gene set size to 1.

It is made available under a CC-BY 4.0 International license .

#### 344 Ethics

345 The study was approved by the Commissie voor Medische Ethiek (CME) of Ghent 346 University Hospital (protocol code: B670201734334 and date of 10/08/2020) and the Comité 347 d'Éthique Institutionnel de la Recherche En Sciences de la Santé (CEIRES) of the Institut de 348 Recherche en Sciences de la Santé (IRSS) (protocol code 50-2020/CEIRES and date of 349 22/10/2020). An independent Data and Safety Monitoring Board (DSMB), comprising an 350 endocrinologist, two pediatricians, a gynecologist, and an ethicist of both Belgian and 351 Burkinabe nationalities, was established prior to the start of the efficacy trial. The DSMB 352 managed remote safety reviews for adverse and serious events at nine and 20 months after the 353 start of enrolment. The MISAME-III trial was registered on *ClinicalTrials.gov* (identifier: 354 NCT03533712).

#### 355 Author Contributions

LD and ST performed the statistical analyses, visualized data, interpreted data, and prepared

the manuscript with contributions from all authors. MRO, EDS, and JLS were responsible for

the sample analysis, interpreted preliminary data and critically reviewed the manuscript.

359 TDC, LCT, CL and PK conceived of the study, acquired funding, and critically reviewed the

360 manuscript. TDC, LCT, LO, YBM, MO, RG, CL, and PK set up the study and supervised the

361 project. TDC, LO, YBM, MO and RG collected samples. TDC, EB, AA, KT, WVC, and MS

362 supervised the data curation and contributed to data interpretation.

363 All authors have read and agreed to the published version of the manuscript.

#### 364 Acknowledgements

- The work is supported by the Bill & Melinda Gates Foundation (OPP1175213). Lishi Deng is
- supported by the China Scholarship Council (Grant No. 202207650056). Steff Taelman is
- 367 supported by the Flemish Agency for Innovation and Entrepreneurship (VLAIO
- 368 HBC.2020.2292). This publication includes data generated at the UC San Diego IGM
- 369 Genomics Center utilizing an Illumina NovaSeq 6000 that was purchased with funding from
- a National Institutes of Health SIG grant (#S10 OD026929). The funders had no role in the
- design and conduct of the study; in the collection, management, analysis, and interpretation
- of the data; or in the preparation, review, or approval of the manuscript.
- 373 The authors thank all participants from Burkina Faso and the data collection team. We thank
- 374 Nutriset (France) for donating the BEP supplements.

It is made available under a CC-BY 4.0 International license .

#### 375 Data Availability Statement

- 376 The informed consent form does not allow sharing of personal data outside the research team.
- 377 Data will be made available through a data-sharing agreement. Please contact
- 378 carl.lachat@ugent.be for any queries. Supporting study documents, including the study
- 379 protocol and questionnaires, are publicly available on the study's website:
- 380 https://misame3.ugent.be (accessed on 23 November 2023).

#### 381 Informed Consent Statement

382 Informed consent was obtained from all subjects involved in the study.

#### 383 Competing Interests

384 The authors have declared no competing interests.

It is made available under a CC-BY 4.0 International license .


#### **Tables and figures**

#### Table 1 Baseline characteristics of study participants

Characteristics	Total ( $n = 152$ )	BEP group $(n = 71)$	IFA group $(n = 81)$	
Health center catchment area, %				
Boni	14.5	15.5	13.4	
Donhoun	10.5	11.3	9.9	
Dougoumato II	18.4	21.1	16.0	
Karaba	12.5	12.7	12.3	
Kari	21.7	21.1	22.2	
Koumbia	18.4	15.5	21.0	
Household level				
Household food insecurity <sup>*</sup> , %	59.9	62.0	58.0	
Wealth index, 0 to 10 poits	$4.64 \pm 1.75$	$4.69 \pm 1.67$	$4.59 \pm 1.82$	
Maternal				
Age, years	$24.27 \pm 5.55$	$23.37 \pm 5.56$	$25.06 \pm 5.46$	
Ethnic group, %				
Bwaba	52.0	49.3	54.3	
Mossi	35.5	39.4	32.1	
Others	12.5	11.3	13.6	
Religion of pregnant women, %				
Animist	22.4	22.5	22.2	
Muslim	45.4	47.9	43.2	
Catholic	6.6	7.0	6.2	
Protestant	23.0	19.7	25.9	
No religion, no animist	2.6	2.8	2.5	
Primary education and above, %	42.1	38.0	45.7	
Number of jobs, %				
0	58.6	64.8	53.1	
1	38.8	33.8	43.2	
2 and above	2.6	1.4	3.7	
Gestational age at birth, weeks	$39.82 \pm 1.72$	$40.04 \pm 1.63$	$39.63 \pm 1.79$	
Parity, %				
0	25.0	29.6	21.0	
1-2	36.8	33.8	39.5	
3 or more	38.2	36.6	39.5	
Weight, kg	$59.10 \pm 10.62$	$57.73 \pm 8.30$	$60.30 \pm 12.23$	
Height, cm	$162.35 \pm 5.87$	$162.13 \pm 4.96$	$162.55 \pm 6.59$	
BMI, kg/m <sup>2</sup>	$22.37 \pm 3.47$	$21.97 \pm 3.16$	$22.71 \pm 3.71$	
Hb, g/dL	$11.88 \pm 1.38$	$11.59 \pm 1.47$	$11.73 \pm 1.43$	
Anemia, Hb <11 g/dL, %	30.3	26.8	33.3	
Number of months receiving EBF	$5.78 \pm 1.01$	$5.91 \pm 0.74$	$5.67 \pm 1.20$	
Values are percentages or means + SDs				

Values are percentages or means ± SDs. \*Assessed using FANTA/USAID's Household Food Insecurity Access Scale.

EBF, exclusive breastfeeding; BMI, body mass index; Hb, hemoglobin; SD, standard deviation.



**Figure 1**: Flow diagram of recruitment, enrollment, and stool sample collection from women and their infants. BEP, balanced energy-protein; IFA, iron-folic acid.

It is made available under a CC-BY 4.0 International license .





Figure 2: (A) Taxonomic compositions of the top-15 most abundant genera (on average across all samples) aggregated on the treatment- and time groups. The lesser abundant genera are grouped into the "Other" category. (B) A PCoA ordination plot of the infant samples. Samples are colored based on the treatment group. (C) A PCoA ordination plot of the maternal samples, colored on treatment group. (D) The taxonomic tree of the strains identified across all samples, colored on phylum. (E) Combined box- and jitter plots of the Shannon diversity indices of the samples, grouped on pre- and postnatal, and on whether the sample was isolated from the infant or the mother, colored on treatment group. Abbreviation: pn12, postnatal 1-2 months; pn56, postnatal 5-6 months; incl., inclusion; tri3, trimester 3.



**Figure 3:** Volcano plots showing differential taxa between two treatment groups at different time points, by ANCOM-BC2. Each point represents an individual taxon, and the position along the x-axis represents logFC in its abundance. The dashed line and labels show the thresholds of statistical and biological significance (Benjamini-Hochberg adjusted *p*-values < 0.05 and |logFC| > 1). The colored dots represent significantly enriched (blue) and depleted (red) taxa that have successfully passed the sensitivity analysis for pseudo-counts. A full table of outputs from ANCOM-BC2 at each time point can be found in Table S2.





Figure 4: Significantly enriched or depleted KEGG pathways associated to BEP supplementation for each time point. Abbreviation: pn12,postnatal 1-2 months; pn56, postnatal 5-6 months; incl., inclusion; tri3, trimester 3. Points are colored according to adjusted p-value and pointsizecorrespondstogenesetsize.



**Figure 5**: The lipopolysaccharide biosynthesis KEGG pathway (map $00540^{63}$ ) in maternal samples during the third trimester of pregnancy. Genes colored in yellow, green, and blue are incrementally less abundantly observed in the BEP-supplemented group. Genes colored in red are more abundantly observed in the BEP-supplemented group.

It is made available under a CC-BY 4.0 International license .

**Table S1**: Nutritional values of the ready-to-use supplementary food for pregnant and lactating women.


Table S2: Results of the differential abundance analyses between intervention groups.

Table S3: Results of the gene set enrichment analyses between intervention groups.


It is made available under a CC-BY 4.0 International license .

This study - maternal 25 Carter-Olm (2023) 20 Bengtsson-Palme (2015) Bases sequenced per sample (Gbp) 15 Rosea (2018) HMP (2012) Brito (2016) 10 Liu (2016) This study - infant Vangay (2018) Costea (2017) Lokmer (2019) Pasolli (2019)Tett (2019) 5 Blackhed (2015) Qin (2012) Qin (2010) Obregon-Tito (2015) Zeevi (2015) Rampelli (2015) Conteville (2019) Pehrsson (2016) Smits (2017) ente (2015) Cle 0 10 100 1000 Number of stool samples


**Figure S1**: The number of samples versus the number of bases sequenced per sample for various gut metagenomic datasets and this study (adapted from (Carter et al., 2023)<sup>64</sup>).



**Figure S2**: The phosphotransferase system KEGG pathway (map02060<sup>63</sup>) in maternal samples during the third trimester of pregnancy. Genes colored in red, yellow, green, and blue are incrementally less abundantly observed in the BEP-supplemented group.



**Figure S3**: The ABC transporters KEGG pathway (map02010<sup>63</sup>) in maternal samples during the third trimester of pregnancy. Genes colored in yellow, green, and blue are incrementally less abundantly observed in the BEP-supplemented group. Genes colored in red are more abundantly observed in the BEP-supplemented group.



**Figure S4**: The flagellar assembly KEGG pathway (map02040<sup>63</sup>) in maternal samples during the third trimester of pregnancy. Genes colored in red, yellow, green, and blue are incrementally less abundantly observed in the BEP-supplemented group.

It is made available under a CC-BY 4.0 International license .

#### References

- Levels and trends in child malnutrition: UNICEF/WHO/World Bank Group joint child malnutrition estimates: key findings of the 2023 edition. https://www.who.int/publications-detail-redirect/9789240073791 (2023).
- Black, R. E. et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. The Lancet 382, 427–451 (2013).
- Martorell, R., Khan, K. & Schroeder, D. G. Reversibility of stunting □: epidemiological findings in children from developing countries. Reversibility Stunting Epidemiol. Find. Child. Dev. Ctries. 48, S45–S57 (1994).
- Victora, C. G., de Onis, M., Hallal, P. C., Blössner, M. & Shrimpton, R. Worldwide Timing of Growth Faltering: Revisiting Implications for Interventions. Pediatrics 125, e473–e480 (2010).
- Victora, C. G. et al. Revisiting maternal and child undernutrition in low-income and middle-income countries: variable progress towards an unfinished agenda. The Lancet 397, 1388–1399 (2021).
- 6. Adu-Afarwuah, S. et al. Small-quantity, lipid-based nutrient supplements provided to women during pregnancy and 6 mo postpartum and to their infants from 6 mo of age increase the mean attained length of 18-mo-old children in semi-urban Ghana: a randomized controlled trial12. Am. J. Clin. Nutr. **104**, 797–808 (2016).
- Argaw, A. et al. Fortified balanced energy–protein supplementation during pregnancy and lactation and infant growth in rural Burkina Faso: A 2 × 2 factorial individually randomized controlled trial. PLOS Med. 20, e1004186 (2023).
- Dewey, K. G. et al. Lipid-based nutrient supplementation in the first 1000 d improves child growth in Bangladesh: a cluster-randomized effectiveness trial1, 2, 3. Am. J. Clin. Nutr. 105, 944–957 (2017).

- Galasso, E., Weber, A. M., Stewart, C. P., Ratsifandrihamanana, L. & Fernald, L. C. H. Effects of nutritional supplementation and home visiting on growth and development in young children in Madagascar: a cluster-randomised controlled trial. Lancet Glob. Health 7, e1257–e1268 (2019).
- Krebs, N. F. et al. Growth from Birth Through Six Months for Infants of Mothers in the "Women First" Preconception Maternal Nutrition Trial. J. Pediatr. 229, 199-206.e4 (2021).
- De Filippo, C. et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl. Acad. Sci. 107, 14691–14696 (2010).
- Grzeskowiak, L. et al. Distinct Gut Microbiota in Southeastern African and Northern European Infants. J. Pediatr. Gastroenterol. Nutr. 54, 812 (2012).
- 13. Olm, M. R. et al. Robust variation in infant gut microbiome assembly across a spectrum of lifestyles. Science **376**, 1220–1223 (2022).
- Bezirtzoglou, E., Tsiotsias, A. & Welling, G. W. Microbiota profile in feces of breast- and formula-fed newborns by using fluorescence in situ hybridization (FISH). Anaerobe 17, 478–482 (2011).
- 15. Stewart, C. J. et al. Temporal development of the gut microbiome in early childhood from the TEDDY study. Nature **562**, 583–588 (2018).
- Ottman, N., Smidt, H., de Vos, W. & Belzer, C. The function of our microbiota: who is out there and what do they do? Front. Cell. Infect. Microbiol. 2, (2012).
- 17. Yatsunenko, T. et al. Human gut microbiome viewed across age and geography. Nature486, 222–227 (2012).
- Alderete, T. L. et al. Early life gut microbiota is associated with rapid infant growth in Hispanics from Southern California. Gut Microbes 13, 1961203 (2021).

- 19. Iddrisu, I. et al. Malnutrition and Gut Microbiota in Children. Nutrients 13, 2727 (2021).
- 20. Subramanian, S. et al. Persistent gut microbiota immaturity in malnourished Bangladeshi children. Nature **510**, 417–421 (2014).
- 21. Arox W, K. et al. Provision of Lipid-Based Nutrient Supplements to Mothers During Pregnancy and 6 Months Postpartum and to Their Infants from 6 to 18 Months Promotes Infant Gut Microbiota Diversity at 18 Months of Age but Not Microbiota Maturation in a Rural Malawian Setting: Secondary Outcomes of a Randomized Trial. J. Nutr. **150**, 918– 928 (2020).
- Kortekangas, E. et al. A Prospective Study on Child Morbidity and Gut Microbiota in Rural Malawi. J. Pediatr. Gastroenterol. Nutr. 69, 431 (2019).
- de Kok, B. et al. Fortified Balanced Energy-Protein Supplements Increase Nutrient Adequacy without Displacing Food Intake in Pregnant Women in Rural Burkina Faso. J. Nutr. 151, 3831–3840 (2021).
- De Kok, B. et al. Prenatal fortified balanced energy-protein supplementation and birth outcomes in rural Burkina Faso: A randomized controlled efficacy trial. PLOS Med. 19, e1004002 (2022).
- Abdill, R. J., Adamowicz, E. M. & Blekhman, R. Public human microbiome data are dominated by highly developed countries. PLOS Biol. 20, e3001536 (2022).
- Kotrba, P., Inui, M. & Yukawa, H. Bacterial phosphotransferase system (PTS) in carbohydrate uptake and control of carbon metabolism. J. Biosci. Bioeng. 92, 502–517 (2001).
- Matsuki, T. et al. A key genetic factor for fucosyllactose utilization affects infant gut microbiota development. Nat. Commun. 7, 11939 (2016).
- Scheppach, W. Effects of short chain fatty acids on gut morphology and function. Gut 35, S35–S38 (1994).

- De Goffau, M. C. et al. Gut microbiomes from Gambian infants reveal the development of a non-industrialized Prevotella-based trophic network. Nat. Microbiol. 7, 132–144 (2021).
- Pickard, J. M., Zeng, M. Y., Caruso, R. & Núñez, G. Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease. Immunol. Rev. 279, 70–89 (2017).
- Gulhane, M. et al. High Fat Diets Induce Colonic Epithelial Cell Stress and Inflammation that is Reversed by IL-22. Sci. Rep. 6, 28990 (2016).
- Di Gesù, C. M., Matz, L. M. & Buffington, S. A. Diet-induced dysbiosis of the maternal gut microbiome in early life programming of neurodevelopmental disorders. Neurosci. Res. 168, 3–19 (2021).
- Chakaroun, R. M., Massier, L. & Kovacs, P. Gut Microbiome, Intestinal Permeability, and Tissue Bacteria in Metabolic Disease: Perpetrators or Bystanders? Nutrients 12, 1082 (2020).
- 34. Bradley, P. H. & Pollard, K. S. Proteobacteria explain significant functional variability in the human gut microbiome. Microbiome **5**, 36 (2017).
- 35. Coats, S. R. et al. The Lipid A Phosphate Position Determines Differential Host Toll-Like Receptor 4 Responses to Phylogenetically Related Symbiotic and Pathogenic Bacteria. Infect. Immun. 79, 203–210 (2011).
- 36. Schromm, A. B. et al. Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion: Bioactivity of LPS determined by lipid A shape. Eur. J. Biochem. 267, 2008–2013 (2000).
- 37. Ravi, A. et al. Linking carbohydrate structure with function in the human gut microbiome using hybrid metagenome assemblies. 2021.05.11.441322 Preprint at https://doi.org/10.1101/2021.05.11.441322 (2021).

- Deutscher, J., Francke, C. & Postma, P. W. How Phosphotransferase System-Related Protein Phosphorylation Regulates Carbohydrate Metabolism in Bacteria. Microbiol. Mol. Biol. Rev. 70, 939–1031 (2006).
- Schneider, E. ABC transporters catalyzing carbohydrate uptake. Res. Microbiol. 152, 303–310 (2001).
- 40. Patrick, S. A tale of two habitats: Bacteroides fragilis, a lethal pathogen and resident in the human gastrointestinal microbiome. Microbiology **168**, 001156 (2022).
- Briliūtė, J. et al. Complex N-glycan breakdown by gut Bacteroides involves an extensive enzymatic apparatus encoded by multiple co-regulated genetic loci. Nat. Microbiol. 4, 1571–1581 (2019).
- Liu, J. et al. Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study. The Lancet 388, 1291–1301 (2016).
- Schnee, A. E. & Petri, W. A. Campylobacter jejuni and associated immune mechanisms: short-term effects and long-term implications for infants in low-income countries. Curr. Opin. Infect. Dis. **30**, 322–328 (2017).
- 44. Bian, X. et al. Campylobacter Abundance in Breastfed Infants and Identification of a New Species in the Global Enterics Multicenter Study. mSphere 5,

10.1128/msphere.00735-19 (2020).

- 45. Xi, M. et al. Functional proteins in breast milk and their correlation with the development of the infant gut microbiota: a study of mother-infant pairs. Front. Microbiol. **14**, 1239501 (2023).
- Laxminarayan, R. & Bhutta, Z. A. Antimicrobial resistance—a threat to neonate survival. Lancet Glob. Health 4, e676–e677 (2016).

- Rodrigues, C. et al. Description of Klebsiella africanensis sp. nov., Klebsiella variicola subsp. tropicalensis subsp. nov. and Klebsiella variicola subsp. variicola subsp. nov. Res. Microbiol. **170**, 165–170 (2019).
- 48. Ouyang, R. et al. Crosstalk between Breast Milk N-Acetylneuraminic Acid and Infant Growth in a Gut Microbiota-Dependent Manner. Metabolites **13**, 846 (2023).
- 49. Vanslambrouck, K. et al. Effect of balanced energy-protein supplementation during pregnancy and lactation on birth outcomes and infant growth in rural Burkina Faso: study protocol for a randomised controlled trial. BMJ Open 11, e038393 (2021).
- 50. Bastos-Moreira, Y. et al. A Multi-Omics and Human Biomonitoring Approach to Assessing the Effectiveness of Fortified Balanced Energy–Protein Supplementation on Maternal and Newborn Health in Burkina Faso: A Study Protocol. Nutrients 15, 4056 (2023).
- 51. Hanley-Cook, G. T. et al. Seasonality and Day-to-Day Variability of Dietary Diversity: Longitudinal Study of Pregnant Women Enrolled in a Randomized Controlled Efficacy Trial in Rural Burkina Faso. J. Nutr. 152, 2145–2154 (2022).
- 52. Huybregts, L. F., Roberfroid, D. A., Kolsteren, P. W. & Van Camp, J. H. Dietary behaviour, food and nutrient intake of pregnant women in a rural community in Burkina Faso. Matern. Child. Nutr. 5, 211–222 (2009).
- 53. Food and Nutrition Board, Institute of Medicine & National Academies. Dietary Reference Intakes (DRIs): Recommended Dietary Allowances and Adequate Intakes, Vitamins. https://www.ncbi.nlm.nih.gov/books/NBK56068/table/summarytables.t2/ (2011).
- 54. Olm, M. R. et al. inStrain profiles population microdiversity from metagenomic data and sensitively detects shared microbial strains. Nat. Biotechnol. **39**, 727–736 (2021).

- 55. McMurdie, P. J. & Holmes, S. phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data. PLoS ONE **8**, e61217 (2013).
- Gruber, S. & Laan, M. J. V. D. tmle: Package for Targeted Maximum Likelihood Estimation. J. Stat. Softw. 51, (2012).
- 57. Jost, L. Entropy and diversity. Oikos 113, 363–375 (2006).
- Lin, H. & Peddada, S. D. Analysis of compositions of microbiomes with bias correction. Nat. Commun. 11, 3514 (2020).
- Huang, R. et al. treeclimbR pinpoints the data-dependent resolution of hierarchical hypotheses. Genome Biol. 22, 157 (2021).
- Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. 102, 15545–15550 (2005).
- Arzamasov, A. A. et al. Human Milk Oligosaccharide Utilization in Intestinal Bifidobacteria Is Governed by Global Transcriptional Regulator NagR. mSystems 7, e00343-22 (2022).
- Wu, T. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. The Innovation 2, 100141 (2021).
- 63. Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. (2000).
- 64. Carter, M. M. et al. Ultra-deep sequencing of Hadza hunter-gatherers recovers vanishing gut microbes. Cell **186**, 3111-3124.e13 (2023).



## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	ltem No	Checklist item	Reported on page No
Fitle and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	1
ntroduction			
ackground and	2a	Scientific background and explanation of rationale	2, 3
bjectives	2b	Specific objectives or hypotheses	3
lethods			
rial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	9
-	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	9
articipants	4a	Eligibility criteria for participants	9
	4b	Settings and locations where the data were collected	9
nterventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	9, 10
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	9, 10
	6b	Any changes to trial outcomes after the trial commenced, with reasons	NA
ample size	7a	How sample size was determined	3
	7b	When applicable, explanation of any interim analyses and stopping guidelines	NA
andomisation:			
Sequence	8a	Method used to generate the random allocation sequence	9 9 9
generation	8b	Type of randomisation; details of any restriction (such as blocking and block size)	9
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	9
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	NA
linding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	NA
	11b	If relevant, description of the similarity of interventions	NA
statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	10 - 12
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	NA
CONSORT 2010 checklist		Page 33	

medRxiv preprint doi: https://doi.org/10.1101/2023.11.24.23298964; this version posted November 27, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

<b>Results</b> Participant flow (a	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and	3
diagram is strongly recommended)	13b	were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons	3
Recruitment	14a	Dates defining the periods of recruitment and follow-up	9
Reorditition	14b	Why the trial ended or was stopped	NA
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	15
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	3
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	3 - 5
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	NA 📅
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	NA made
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	NA available
Discussion			labl
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	8 <sup>10</sup>
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	8 under 5, 6 er
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	<u>م</u>
Other information			<u>- 0 - 0</u> Сс. ВҮ
Registration	23	Registration number and name of trial registry	
Protocol	24	Where the full trial protocol can be accessed, if available	13 40 Inter
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	13
© 2010 Schulz et al. This unrestricted use, distribut	is an O tion, and	Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC M pen Access article distributed under the terms of the Creative Commons Attribution License ( <u>http://creativecommons.org/licenses/by/2.0</u> ), v I reproduction in any medium, provided the original work is properly cited.	which permits
*We strongly recommend reading CONSORT exter	l reading	this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant or cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials	, we also recommend

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up-to-date references relevant to this checklist, see www.consort-statement.org.